In conclusion, the study demonstrated that CAR-T therapy and PD-1 blockade yielded better outcomes than CAR-T therapy alone, with a higher rate of complete responses observed, particularly in HL patients (140). Here, PDCD1 is linked to Hodgkins lymphoma.